AORT
ARTIVION, INC.
NYSE · Healthcare · Medical - Devices · US
$26.10
+10.08%Oct 22, 2026, 20:10 UTC
Artivion announced that it will release its third-quarter 2026 financial results after market close on November 5, 2026, and hold a teleconference call and live webcast at 4:30 p.m. that day.
Source:Aug 6, 2026, 20:05 UTC
Artivion completed the acquisition of Endospan Ltd.
Source:Aug 6, 2026, 20:05 UTC
Artivion announced U.S. FDA PMA approval of the AMDS Hybrid Prosthesis.
Source:Aug 6, 2026, 20:05 UTC
Artivion reported second quarter 2026 revenue of $125.8 million, up 11% year-over-year, with a net loss of $13.5 million and non-GAAP net income of $6.3 million.
Jul 1, 2026, 15:16 UTC
Artivion received FDA approval for its AMDS Hybrid Prosthesis device.
Source:Jun 29, 2026, 11:00 UTC
The U.S. FDA approved Artivion's premarket approval application for the AMDS Hybrid Prosthesis.